Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966190 | 0.88 | HRH3 (0.55) | GRIN1GRIN2BDRD2DRD4DRD3 | |
| SCHEMBL6966434 | 0.79 | HRH3 (0.63) | GRIN1GRIN2BHRH3 | |
| SCHEMBL6972349 | 0.79 | GRIN2B (0.61) | GRIN2BHRH3 | |
| SCHEMBL6974388 | 0.78 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7287443 | 0.76 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6962072 | 0.76 | GRIN1 (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7287356 | 0.74 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6969549 | 0.74 | DRD2 (0.79) | ADRA1ADRD2DRD3 | |
| SCHEMBL21651971 | 0.73 | GRIN2B (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7294433 | 0.73 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | claimed |
| EP-0869791-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | EP | claimed |
| EP-0869791-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023214-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0869791-B1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6448270-B1 | BICYCLIC HETEROARYL ACETYLENES; NEUROPROTECTIVE AGENTS; STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTIC INDUCED HEARING LOSS, MIGRAINES, CHRONIC PAIN, GLAUCOMA | WARNER-LAMBERT COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6130234-A | 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0869791-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0869791-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023214-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | GRIN3B, OPRM1, GRIN3A | GRIN2D 7/4885GRIN3B 1/4885GRIN1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.